PA
XLRN

Perceptive Advisors’s Acceleron Pharma XLRN Stock Holding History

Perceptive Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-226,760
Closed -$28.5M – 168
2021
Q2 		$28.5M Buy
+226,760
New +$28.6M 0.37% 63
2020
Q2 		– Sell
-6,813
Closed -$583K – 146
2020
Q1 		$583K Buy
+6,813
New +$530K 0.02% 100
2019
Q1 		– Sell
-905,017
Closed -$39.9M – 126
2018
Q4 		$39.9M Sell
905,017
-623,188
-41% -$31.1M 1.52% 21
2018
Q3 		$87.5M Hold
1,528,205
– – 2.34% 7
2018
Q2 		$74.1M Buy
1,528,205
+11,946
+0.8% +$435K 1.94% 11
2018
Q1 		$59.3M Sell
1,516,259
-100,000
-6% -$4.25M 1.66% 18
2017
Q4 		$68.6M Hold
1,616,259
– – 2.27% 10
2017
Q3 		$60.3M Buy
1,616,259
+905,000
+127% +$31.4M 2.3% 11
2017
Q2 		$21.6M Buy
711,259
+47,402
+7% +$1.37M 1.09% 27
2017
Q1 		$17.6M Buy
663,857
+43,870
+7% +$1.16M 1% 31
2016
Q4 		$15.8M Buy
619,987
+30,097
+5% +$954K 1.13% 23
2016
Q3 		$21.3M Sell
589,890
-13,146
-2% -$435K 1.38% 13
2016
Q2 		$20.5M Sell
603,036
-200,000
-25% -$6.5M 1.42% 17
2016
Q1 		$21.2M Buy
803,036
+527,000
+191% +$15.3M 1.86% 9
2015
Q4 		$13.5M Hold
276,036
– – 1% 26
2015
Q3 		$6.87M Hold
276,036
– – 0.55% 46
2015
Q2 		$8.73M Sell
276,036
-60,000
-18% -$1.94M 0.53% 45
2015
Q1 		$12.8M Buy
336,036
+18,400
+6% +$732K 0.99% 26
2014
Q4 		$12.4M Sell
317,636
-127,364
-29% -$4.44M 1.04% 28
2014
Q3 		$13.5M Buy
445,000
+145,000
+48% +$4.08M 1.36% 23
2014
Q2 		$10.2M Buy
+300,000
New +$10M 1% 31

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Perceptive Advisors's XLRN Position: Q3 2021 in Review

Perceptive Advisors sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 226,760 shares — an estimated $28.5M sold.

Perceptive Advisors first reported a position in XLRN in Q2 2014 and held it in 21 quarters. The position peaked at $87.5M in Q3 2018. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

  • Perceptive Advisors reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
  • Perceptive Advisors sold 226,760 Acceleron Pharma shares in Q3 2021, an estimated $28.5M.
  • Perceptive Advisors first reported a position in Acceleron Pharma in Q2 2014 and held it in 21 quarters.
  • Perceptive Advisors's Acceleron Pharma position peaked at $87.5M in Q3 2018.
  • 330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Perceptive Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.